Key points from article :
Researchers found a new pill that selectively keeps free radicals from being produced in mice.
Inhibits free radical production at a mitochondrial site that prevents and treats metabolic syndrome, by preventing/ reversing insulin resistance.
“Mitochondrial radical production drives many chronic diseases of aging, and blocking the production of free radicals is a viable disease-treating and anti-aging intervention,” - Martin Brand, Senior investigator.
Orally bioavailable compound, S1QEL1.719, was given both prophylactically and therapeutically to mice with metabolic syndrome.
S1QEL1s act on site IQ in mitochondrial complex I, which is one of the four protein complexes involved in energy production.
Treatment decreased fat accumulation, strongly protected against decreased glucose tolerance and protecting against insulin resistance.
Current literature strongly implicates complex I in different diseases, from metabolic syndrome to Alzheimer’s, fatty liver disease, and noise-induced hearing loss, as well as the underlying aging process itself.
S1QELs specifically inhibit radical production at the IQ site... and do not disrupt normal mitochondrial functioning.
“Just inhibiting this specific site improves the whole redox environment and prevents metabolic disease, and that is amazing,” - Brand.
Collaborative research by Buck Institute and Calico Labs; published in Free Radical Biology and Medicine.
